Tag: Autonomix Medical

Following the announcement of encouraging topline results from an ongoing clinical trial, shares of Autonomix Medical, Inc. (NASDAQ: AMIX) have surged. AMIX stock increased by 45.02%, reaching $14.85, reflecting investor confidence in the company’s innovative approach to managing pancreatic cancer pain through advanced nerve ablation technology.

Promising Clinical Outcomes

In order to assess the safety and efficacy of transvascular energy for the ablation of troublesome nerves in patients with pancreatic cancer, Autonomix (AMIX) has announced encouraging first results from the first 15 patients recruited in its proof-of-concept experiment.

According to the data thus far, patients’ quality of life has improved and their pain has significantly decreased, underscoring the technology’s potential to revolutionize pain treatment in pancreatic cancer.

Autonomix’s platform shows promise in providing an alternative to conventional treatments like opioids and invasive ethanol injections, which often result in limited relief and possible adverse effects.

Progress and Expansion of Clinical Study

Achieving 60% enrollment in the clinical study marks a key milestone for Autonomix, advancing its goal of completing enrollment by the end of the calendar year. The rapid enrollment pace reflects the demand for alternative pain management solutions in electrophysiology.

Additionally, the study protocol was amended to collect crucial bio-measurements, including tumor encroachment on blood vessels, which may enhance the accuracy of nerve ablation therapy.

The study has also refined its inclusion criteria, now focusing on patients reporting severe pain levels of 7 or higher on the Visual Analog Scale (VAS), as self-reported by patients rather than determined solely by physicians. Upon completion, the study will include 20 patients, with final data to inform further development and application of Autonomix’s technology.

Advanced Technology Platform with Precision Ablation

Autonomix’s unique technology platform is a catheter-based microchip sensing array antenna, capable of detecting neural signals with up to 3,000 times the sensitivity of current technologies.

This precision-guided approach enables the identification, targeting, and ablation of pain-associated nerves through radiofrequency ablation, presenting a promising treatment paradigm across pain management, hypertension, and cardiology.

Autonomix’s technology has the potential to eliminate opioid dependency and dramatically improve patient outcomes, offering a breakthrough in chronic pain treatment alternatives.

Autonomix Medical, Inc. (NASDAQ: AMIX) shares surged significantly today, climbing 124.24% to $17.29, following the announcement of promising preliminary results from the company’s ongoing proof-of-concept human clinical trial. The trial focuses on evaluating the safety and efficacy of transvascular energy delivery to ablate specific problematic nerves and reduce pain in patients suffering from pancreatic cancer.

Encouraging Early Data in Pain Management

The clinical trial involved five “lead-in” patients, with three treated via femoral access and two through brachial access. Results revealed that the patients treated with femoral access experienced substantial pain relief, while those treated through brachial access showed no improvement.

The data reported from the responder group indicate a significant reduction in pain, as measured by the Visual Analog Scale (VAS), with average pain scores dropping from 8.0 pre-procedure to 1.33 within 4-6 weeks post-procedure. Notably, all responding patients were able to eliminate opioid use entirely within this period.

Implications for Pancreatic Cancer Patients

Late-stage pancreatic cancer patients often endure chronic pain, leading to dependence on opioids. These medications come with severe side effects, including addiction and overdose risk.

The trial’s preliminary findings suggest that Autonomix’s novel approach may offer a groundbreaking alternative, effectively reducing pain and allowing patients to discontinue opioid use. This development represents a potential shift in interventional pain management for pancreatic cancer patients, addressing a critical unmet medical need.

Autonomix’s Innovative Technology Platform

Autonomix’s proprietary platform utilizes a catheter-based microchip sensing array antenna capable of detecting neural signals with unparalleled sensitivity—3,000 times greater than existing technologies. Once the target nerves are identified, the company’s radio frequency (RF) ablation technology selectively destroys them, offering a precision-based approach to managing pain.

This method contrasts with traditional treatments like opioids and invasive ethanol injections, which often provide limited relief and carry significant risks. With the trial set to complete enrollment by the end of 2024, Autonomix’s innovative technology could mark a transformative advance in treating chronic pain and other conditions such as hypertension and cardiology.